MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 Mar;21(3):373-386.
[3]Sequist LV, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentr...
[1] Lu S, et al. A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation. WCLC 2023; OA21.03. [2] Paik PK, et al. Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study. ...
MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 Mar;21(3):373-386.
患者于 2023 年 3 月 14 日开始接受赛沃替尼 400 mg qd 治疗,5 月疗效评估显示肺部病灶实现疾病稳定(SD),脑部病灶实现部分缓解(PR)。于 6 月开始增加赛沃替尼剂量至 600 mg qd 治疗,期间疗效评估提示肺部病灶大致同前,但脑转移灶缩小。截至目前,患者的 PFS 已超过 21 个月,且患者治疗期间患者未发生明显...
7.Sequist LV,Han JY,Ahn MJ,et al.Osimertinib plus savolitinib in patients with EGFR mutation-positive,MET-amplified,non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors:interim results from a multicentre,open-label,phase 1b study.LANCET ONCOLOGY.2020;21(3):373-386...
近日,《国家基本医疗保险、工伤保险和生育保险药品目录(2022年)》正式发布,并于2023年3月1日正式落地实施。其中高选择性MET抑制剂赛沃替尼成功纳入,成为此次唯一*列入新版国家医保目录的MET靶向药物。 赛沃替尼是我国本土原研1类新药,于2021年在国内获批上市,适用于含铂化疗后疾病进展或不耐受标准含铂化疗的、MET 14...
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. Lancet Oncol, 2020, 21(3):373-386. DOI: 10.1016/S1470-...
5. 孙曼，李晓敏.晚期非小细胞肺癌MET 14外显子跳跃突变的治疗新进展[J].中国癌症防治杂志 2023年4月第15卷第2期：239-244.6.J. Yang.1379P - Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations[J].ESMO Congress 2023....
[8]https://oncologypro.esmo.org/meeting-resources/esmo-congress/preliminary-results-of-phase-ii-kunpeng-study-of-vebreltinib-in-patients-pts-with-advanced-nsclc-harboring-c-met-alterations.